by Eclosion Team | Nov 16, 2015 | Uncategorized
GeNeuro Successfully Completes Phase 2a Clinical Study with Novel Approach to Treat Multiple Sclerosis First in Class GNbAC1 mAb Targets Human Endogenous RetroVirus Geneva, Switzerland and Lyon / Archamps, France – November 4, 2013 – GeNeuro announced today...
by Eclosion Team | Nov 16, 2015 | Uncategorized
Geneva, Switzerland and Archamps, France, September 9, 2013 – Genkyotex, the leading developer of NOX enzyme inhibitors, announced today that the U.S. Food and Drug Administration has approved the company’s Investigational New Drug (IND) application to begin a Phase...
by Eclosion Team | Nov 16, 2015 | Uncategorized
GeNeuro SA announces today the successful completion of its phase I clinical study with GNbAC1, a humanized monoclonal antibody targeting a human endogenous retrovirus, to treat multiple sclerosis. The randomized, double-blind, placebo-controlled, phase I study of...